The myxobacterial antibiotics archazolid and apicularen are highly efficient and specific novel inhibitors of V-ATPases. While archazolid at least partly shares a common binding site with the plecomacrolides bafilomycin and concanamycin, apicularen adheres to an independent binding site.
No takes yet. Share an insight, caveat, or question.
Huss et al. (2005) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: